Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.
John C FlickingerJagmohan SinghRobert CarlsonElinor LeongTrevor R BaybuttJoshua BartonEllen CaparosaAmanda PattisonJeffrey A RappaportJamin RohTingting ZhanBabar BashirScott A WaldmanAdam E SnookPublished in: Journal for immunotherapy of cancer (2021)
These data suggest that Ad5.F35-based vaccines targeting GUCY2C, or other tumor or pathogen antigens, may produce clinically relevant immune responses in more (≥90%) patients compared with Ad5-based vaccines (~50%).
Keyphrases
- immune response
- end stage renal disease
- cancer therapy
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- cell therapy
- electronic health record
- toll like receptor
- machine learning
- escherichia coli
- dengue virus
- big data
- deep learning
- zika virus
- mesenchymal stem cells
- klebsiella pneumoniae
- multidrug resistant
- patient reported